Surrey Heartlands

Joint Formulary & PAD

Sirolimus - Angiofibroma from tuberous sclerosis complex

You are here : Home > Formulary Search > Sirolimus - Angiofibroma from tuberous sclerosis complex

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Gel
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Sirolimus
Indication :
Angiofibroma from tuberous sclerosis complex
Group Name :
Keywords :
Brand Names Include :
Hyftor
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Sirolimus is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Angiofibroma from tuberous sclerosis complex.

  • No records returned.

Committee Recommendations (1)

22 Nov 23 - Not Set

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

NICE are expected to publish guidance on this drug (date tbc) and this will be considered by the APC within 90 days of publication